Chinese Biotech Startup Genecast Bags $149 Million in Series E Funding Round

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING: Geely Leads $141 Million Round for Tsinghua-Linked Robotics Startup; Intel Pivots to Custom Chips to Tap China’s Trillion-Yuan Computing Markets; Wingtech Demands Return of Nexperia Control After Dutch Freeze Pause

LATEST: AI Keeps China, U.S. From Decoupling Despite Trade Tensions, Insiders Say; Wingtech Demands Return of Nexperia Control After Dutch Freeze Pause; Intel Pivots to Custom Chips to Tap China’s Trillion-Yuan Computing Markets; Geely Leads $141 Million Round for Tsinghua-Linked Robotics Startup; China’s Giant Neutrino Detector Delivers First Results With Record Precision; China Unicom Taps Veteran Executive as Chairman to Navigate Telecom Transition; Chinese Self-Driving Firms Accelerate Into Middle East, Southeast Asia; Baidu Posts Record Revenue Decline as Ad Business Falters; Xiaomi’s EV, AI Units Post First Quarterly Profit; China’s Agricultural Drone Makers Pivot to Smarter Navigation as Size Race Ends; Alibaba Renames AI App to Stand Out in China’s Crowded Chatbot Market; Investors Flock to Chinese eVTOLs Chasing Regulatory Green Lights; Nexperia Headquarters Rachets Up Feud With China Unit With Salvo of Accusations; Robot-Maker Unitree Steps Closer to China IPO; Tencent Says Talks With Apple on WeChat Game Fees Are Advancing; Baidu Unveils Ambitious AI Chip Roadmap, Targeting 1 Million-Card Cluster by 2030; Tencent’s Profit Rises 19% on Overseas Gaming and AI-Powered Ad Surge; Caixin Summit: Design, Commercialization Key to China’s Low-Altitude Economy Taking Off, Industry Insider Says; China’s Robotics Revenue Soars as Industry Races to Crack Embodied AI; U.S. Formally Suspends Sweeping Export Control Rule for One Year After China Trade Talks

By Ding Yi / Oct 27, 2020 05:22 PM / Finance

Genecast Biotechnology, a Chinese biotech startup that specializes in second-generation sequencing technology and bioinformatics, has closed its 1 billion yuan ($149 million) series E funding round led by China Structural Reform Fund, the company said in a statement on Monday.

Other investors include Taikang Asset Management, CCB Private Equity Investment Management, Hillhouse Capital’s venture capital unit GL Ventures and China Renaissance, according to the statement.

Genecast Biotechnology will use the proceeds from the financing round to develop new diagnostics products for tumors, accelerate the registration and application of its in vitro diagnostic devices and expand its marketing channels, according to the statement.

Founded in 2014, the Wuxi, Jiangsu province-based company has regional sales and services branches across 12 major cities in China. It has also built ties with nearly 500 top hospitals in China and more than 20 drug makers globally, according the company’s website.

Contact reporter Ding Yi (yiding@caixin.com)

Share this article

Open WeChat and scan the QR code